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Despite the importance of Th17 cells in autoimmune
diseases, it remains unclear how they control
other inflammatory cells in autoimmune tissue dam-
age. Using a model of spontaneous autoimmune
arthritis, we showed that arthritogenic Th17 cells
stimulated fibroblast-like synoviocytes via inter-
leukin-17 (IL-17) to secrete the cytokine GM-
CSF and also expanded synovial-resident innate
lymphoid cells (ILCs) in inflamed joints. Activated
synovial ILCs, which expressed CD25, IL-33Ra, and
TLR9, produced abundant GM-CSF upon stimulation
by IL-2, IL-33, or CpG DNA. Loss of GM-CSF produc-
tion by either ILCs or radio-resistant stromal cells
prevented Th17 cell-mediated arthritis. GM-CSF pro-
duction by Th17 cells augmented chronic inflamma-
tion but was dispensable for the initiation of arthritis.
We showed that GM-CSF-producing ILCs were pre-
sent in inflamed joints of rheumatoid arthritis pa-
tients. Thus, a cellular cascade of autoimmune
Th17 cells, ILCs, and stromal cells, via IL-17 and
GM-CSF, mediates chronic joint inflammation and
can be a target for therapeutic intervention.
INTRODUCTION
Proinflammatory cytokines such as IL-1, IL-6, IL-17, IL-23,
GM-CSF, and TNF-a are important in the development andmain-
tenance of chronic inflammatory disorders such as autoimmune
disease. Neutralization of these cytokines or blockade of their
receptors is effective in hampering the progression of tissue1220 Immunity 48, 1220–1232, June 19, 2018 ª 2018 Francis Crick In
This is an open access article under the CC BY license (http://creativeinflammation and inducing long-term remission in autoimmune
disorders (ChoandFeldman, 2015).Recent genome-wide associ-
ation studies of immune-mediated diseases have revealed com-
mon inflammatory pathways, involving the genes encoding these
cytokines and receptors, in various autoimmunediseases (Parkes
et al., 2013). It remains to be determined, however, how key in-
flammatory cytokines control non-lymphoid as well as lymphoid
target cells in autoimmune tissue inflammation, how environ-
mental factors, aswell as genetic factors, contribute to the inflam-
mation, and how the cytokine-dependent inflammatory pathways
can be targeted to treat or prevent autoimmune diseases.
IL-17-producing T helper (Th17) cells play critical roles for host
defense against infectious pathogens but can also mediate
various autoimmune or inflammatory reactions. They express
the lineage defining transcription factor Rorgt and require IL-6
and TGF-b for their differentiation and IL-1 and IL-23 for their ter-
minal effector functions (Ivanov et al., 2006; McGeachy et al.,
2009; Veldhoen et al., 2006). In rheumatoid arthritis (RA), for
example, it has been shown that various inflammatory cytokines
including TNF-a, IL-1, and IL-6 are involved in joint inflammation
and that T cells interact with tissue-resident macrophage-like or
fibroblast-like synoviocytes (FLSs) in destroying cartilage and
bone in the joint (Bartok and Firestein, 2010). It still remains un-
clear, however, how arthritogenic Th17 cells mediate chronic tis-
sue inflammation in the joint via local cytokine and cellular
networks.
GM-CSF is a key proinflammatory cytokine for the activation
of dendritic cells (DCs) and macrophages; for example, DCs
respond to GM-CSF to secrete IL-6 and IL-23, which sustain
pathogenic Th17 cells in vivo (Sonderegger et al., 2008). More-
over, IL-1 and IL-23 signaling drives Rorgt-expressing Th17 cells
to secrete GM-CSF, perpetuating autoimmune inflammation,
for example, in mouse experimental autoimmune encepha-
lomyelitis (EAE) (Codarri et al., 2011; El-Behi et al., 2011).
The antigen-presentation capacity of monocytes and synovialstitute. Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
Figure 1. GM-CSF-Producing THelperCells
Are Dispensable for GM-CSF-Dependent
Autoimmune Arthritis Development
(A) Intracellular IL-17, IFN-g, and GM-CSF staining
of CD4+ T cells from popliteal LNs or inflamed
joints.
(B) Proportion of cytokine-producing cells in CD4+
T cells from individual mice as shown in (A). Ver-
tical bars mean SD (n = 3).
(C) Arthritis scores assessed in individual SKG,
Csf2/ SKG, or Il17a/ SKG mice (n = 20 each)
3 months after single i.p. injection of 20 mg
mannan.
(D) Intracellular IL-17, IFN-g, andGM-CSF staining
of CD4+ T cells from inflamed joints of Il17aCre
R26ReYFP SKG mice.
(E) Arthritis development after adoptive transfer of
CD4+ T cells from WT or Csf2/ SKG mice into
Rag2/ mice (n = 17 each, SEM). The severity of
arthritis wasmonitored every week after transfer of
1 3 106 CD4+ T cells.
(F) Intracellular IL-17 and GM-CSF staining of
CD4+ T cells from spleens and inflamed joints of
Rag2/ mice with CD4+ T cells transfer as
shown in (E).
*p < 0.05, **p < 0.01. Data are representative of
three independent experiments (A, B, D, and F) or
pooled from three experiments (C and E).inflammatorymacrophages can also be enhanced by stimulation
with GM-CSF through upregulation of MHC class II expression
(Alvaro-Gracia et al., 1989). In addition, GM-CSF signaling
evokes an inflammatory signature in CCR2+Ly6Chi monocytes
and drives them to induce tissue damage (Croxford et al.,
2015). GM-CSF thus appears to possess pleiotropic effects on
monocytes and/or DCs and Th17 cells, augmenting the activa-
tion of innate and adaptive immune cells and amplifying tissue
inflammation.
The SKG strain of mice, carrying a point mutation in the gene
encoding the T cell receptor (TCR)-proximal signaling molecule
ZAP-70, develops CD4+ T cell-mediated autoimmune arthritis,
which clinically and immunologically resembles RA in humans
(Hata et al., 2004; Sakaguchi et al., 2003). The mice spon-
taneously develop the disease in a microbially conventional
environment but not under a specific-pathogen-free (SPF) condi-
tion. Yet the disease can be induced in SPF SKG mice by
stimulation of innate immunity via Toll-like receptors (TLRs),
the Dectin pathway, or complement activation pathways
(Hashimoto et al., 2010; Yoshitomi et al., 2005). We previouslyImmdemonstrated, by using SKG mice, how
self-reactive T cells are generated in the
process of thymic-positive and -negative
selection (Sakaguchi et al., 2003),
become activated in the periphery by
recognizing self-antigens, differentiate
into arthritogenic Th17 cells upon stimu-
lation of innate immunity (Hirota et al.,
2007a), migrate into the joints (Hirota
et al., 2007b), and aggress self-antigens
expressed by synoviocytes (Ito et al.,
2014). In addition, dysfunction of Foxp3+regulatory T cells due to the ZAP-70 mutation facilitates autoim-
mune T cells to expand, become activated, and exert their
effector functions, causing autoimmune diseases in awide spec-
trum of organs or tissues (Tanaka et al., 2010). These features
make this spontaneous model of autoimmune arthritis suitable
for elucidating how Th17 cells mediate autoimmune diseases,
especially RA, via interacting with other lymphoid and non-
lymphoid cells at the inflammation site and controlling their pro-
duction of inflammatory cytokines.
In this report, we showed via the SKG model of autoimmune
arthritis that arthritogenic Th17 cells orchestrated the progres-
sion of chronic joint inflammation by stimulating radio-resistant
stromal cells including FLSs to secrete GM-CSF and subse-
quently by expanding GM-CSF-producing innate lymphoid cells
(ILCs). Notably, GM-CSF secretion from ILCs was regulated by
IL-2, the alarmin IL-33, and endogenous TLR-9 ligands released
from damaged tissue-resident cells, in inflamed joints. The re-
sults demonstrate how antigen-specific self-reactive T cells
stimulate the local cellular and cytokine networks that drive
chronic tissue inflammation.unity 48, 1220–1232, June 19, 2018 1221
Figure 2. GM-CSF from Non-T Cells Is
Crucial for the Initiation of Autoimmune
Arthritis
(A) Experimental design of adoptive transfer of
CD4+ T cells from WT or Csf2/ SKG mice into
Rag2/ or Csf2/Rag2/ mice. Arthritis scores
of four groups (a–d) of mice were assessed
3 months after transfer of 1 3 106 CD4+ T cells.
(B) Arthritis scores of the four groups mice (n = 15
or 16 each) shown in (A). Horizontal bars indicate
the means.
(C) Representative joint histology of the groups
shown in (A). Scale bars indicate 200 mm.
(D) Flow cytometry of splenic CD4+ T cells stained
for intracellular IL-17 and GM-CSF or IFN-g.
(E) Proportion of IL-17-producing CD4+ T cells
from individual mice as shown in (D). Vertical bars
mean SD (n = 3).
**p < 0.01. Data are representative of three inde-
pendent experiments (C–E) or pooled from three
independent experiments (B).RESULTS
GM-CSF as a Crucial Inflammatory Mediator of
Autoimmune Arthritis
A single injection of 20 mg mannan, an activator of the lectin
pathway for complement activation, is able to synchronously
evoke T cell-mediated autoimmune arthritis within 2–3 weeks
in SPF SKG mice with an increase in Th17 cells in lymph nodes
and joints (Hashimoto et al., 2010). In the draining lymph nodes
and inflamed joints of mannan-treated SKGmice, approximately
2% and 7%, respectively, of CD4+ T cells co-expressed IL-17
and GM-CSF, but not IFN-g (Figures 1A and 1B). In addition,
GM-CSF (encoded by Csf2)-deficient (Csf2/) SKG mice were
highly resistant to the induction of autoimmune arthritis by
mannan as were Il17a/ SKG mice, indicating a crucial role of
GM-CSF for arthritis development in SKGmice (Figure 1C; Hirota
et al., 2007a).
To determine the origin of such GM-CSF-producing cells in
arthritic SKG mice, we generated IL-17-fate reporter SKG mice
by crossing SKG mice with Il17aCre and R26ReYFP fate reporter
strains (Hirota et al., 2011). Following mannan treatment, more
than 30%ofCD4+ T cells in inflamed jointswere eYFP+, indicating
that theywereproducing IL-17or hadonceproduced the cytokine
(exTh17 cells) (Figure 1D). In addition, one-third of eYFP+ cells
were producing GM-CSF, indicating that IL-17-producing CD4+
T cells produced GM-CSF in inflamed joints. Also, only 5% of1222 Immunity 48, 1220–1232, June 19, 2018eYFP+ cells were producing IFN-g, sug-
gesting that differentiation toward Th1-
like cells was not the main cell fate of
Th17 or exTh17 cells in this model, in
contrastwith EAE, inwhich the vastmajor-
ity of exTh17 cells were producing IFN-g
(Hirota et al., 2011).
Next, we adoptively transferred CD4+
T cells from Csf2/ or wild-type (WT)
SKG mice into Rag2/ mice to deter-
mine the pathogenicity of GM-CSF-pro-
ducing CD4+ T cells (Figure 1E). Csf2/SKG CD4+ T cells were able to induce autoimmune arthritis in
all the recipient mice, although arthritis was significantly less se-
vere than that induced by WT SKG CD4+ T cell transfer. Analysis
of IL-17 and GM-CSF production by CD4+ T cells in the spleen
and inflamed joints revealed that IL-17-producing CD4+ T cells,
which were crucial for initiating SKG autoimmune arthritis (Hirota
et al., 2007a), had similarly differentiated from Csf2/ or WT
SKG CD4+ T cells (Figure 1F).
These results demonstrated that both T cell-derived and
non-T cell-derived GM-CSF contributed to joint inflammation in
SKG mice and that GM-CSF from Th cells was not mandatory
for this induction of autoimmune arthritis.
GM-CSF Secreted from Non-T Cells Is Crucial for
Initiating Autoimmune Arthritis
To further assess the possible contribution of GM-CSF from non-
CD4Tcells to arthritis development,we transferredCsf2/ orWT
SKG CD4+ T cells into Rag2/ or Csf2/Rag2/ mice (Fig-
ure 2A). Transfer of Csf2/ SKG CD4+ T cells induced histologi-
cally evident arthritis in Rag2/ mice although the arthritis was
macroscopically less severe than WT SKG CD4+ T cell transfer
(Figures 2B and 2C). In contrast, not only Csf2/ SKG CD4+
T cells but also WT SKG CD4+ T cells completely failed to induce
arthritis macroscopically and histologically in Csf2/Rag2/
mice. Intracellular cytokine staining of transferred Csf2/ or WT
SKG CD4+ T cells revealed that both populations were activated
Figure 3. Induction of GM-CSF in FLSs
Stimulated with IL-17
(A) Quantitative RT-PCR analysis for the expres-
sion of designated genes in IL-17-stimulated
FLSs. FLSs (2.5 3 104) were stimulated with
50 ng/mL rmIL-17 and harvested at the indicated
time points. mRNA expression is presented rela-
tive to the expression of Hprt1.
(B) Quantitative RT-PCR analysis for the expres-
sion of designated genes in synoviocytes from
Rag2/ mice with CD4+ T cell transfer.
CD45Podoplanin+ synoviocytes (3 3 104) were
sorted from inflamed joints of Rag2/
mice 4 weeks after transfer of 1 3 106 SKG or
Il17a/ SKG CD4+ T cells. Vertical bars mean SD
(n = 3).
Data are representative of two independent
experiments.and had differentiated into IL-17-producing CD4+ T cells regard-
less of whether the hosts produced GM-CSF or not (Figures 2D
and2E). Thus, the failure inarthritis development following transfer
of CD4+ T cells into Csf2/ hosts could be attributed not to
impaired Th17 cell differentiation but to impaired GM-CSF pro-
duction by certain host non-T cells stimulated by Th17 cells.
FLSs Secrete GM-CSF in Response to IL-17
We next attempted to determine the non-T cell source of GM-
CSF in inflamed joints in SKG mice. FLSs are known to be key
effector cells capable of secreting large amounts of pro-inflam-
matory mediators (e.g., tissue-degrading enzymes and cyto-
kines such as TNF-a), which destroy the cartilage and bone in
SKG arthritis as in human RA (Bartok and Firestein, 2010; Hata
et al., 2004). Gene expression analysis of FLSs that were freshly
isolated from SKG arthritic joints and stimulated in vitro with re-
combinant IL-17 revealed quick upregulation within 1–3 hr of the
expression of Csf2, Ccl20, Cxcl1, Cxcl5, Il6, Nfkbiz, Lif, and
Zc3h12a (Figure 3A). Yet activated FLSs themselves neither ex-
pressed GM-CSF receptor-alpha nor responded to recombinant
GM-CSF (Figure S1A and data not shown). The cells predomi-
nantly expressing GM-CSF receptor-alpha in inflamed joints
were CD11b+Ly-6C+Ly-6G inflammatory monocytes, as re-
ported previously with EAE (Croxford et al., 2015), indicating
that this population could be amain target of GM-CSF in the joint
(Figure S1B). In addition, cell transfer of WT, but not Il17a/,
SKG CD4+ T cells into Rag2/ mice significantly induced
Csf2, Ccl20, and Il6 transcription in CD45podoplanin+ synovio-
cytes that were purified from the joints 4 weeks after cell transferImm(Figure 3B). Thus, one of the cellular
targets of arthritogenic Th17 cells is
FLSs, which secrete GM-CSF upon
IL-17 stimulation.
GM-CSF-Producing Synovial-
Resident ILCs Expand in Arthritic
Joints and Augment Autoimmune
Arthritis
Next, in order to search for a potential
hematopoietic source of GM-CSF otherthan T cells in joint inflammation, we prepared single-cell sus-
pensions from enzyme-digested inflamed joints in Rag2/
mice that had received Csf2/ or WT SKG CD4+ T cells. By
intracellular GM-CSF staining, CD4+ and non-CD4+ T cell popu-
lations in CD45+ hematopoietic cells contained similar percent-
ages of GM-CSF-producing cells in Rag2/ mice transferred
with WT SKG CD4+ T cells, whereas non-CD4 cells were the
only source of GM-CSF in those transferred with Csf2/ SKG
CD4+ T cells (Figure 4A). To characterize the non-CD4 source
of GM-CSF, various CD45+ cell populations were purified from
SKG inflamed joints by the use of cell lineage markers and as-
sessed for their cytokine expression by quantitative RT-PCR
(Figure 4B). The vast majority of joint-infiltrating cells were
CD11b+Ly-6G inflammatory monocytes or macrophages and
CD11b+Ly-6G+ neutrophils, a common feature of Th17 cell-
mediated inflammation (Iwakura et al., 2011). However, these
populations of neutrophils and inflammatory monocytes did
not express Csf2 while they specifically expressed Il1b. In
contrast, lymphoid populations including CD4+ T cells and line-
age marker-negative ILCs expressed Csf2 but not Il1b. 2% to
4% of CD45+ lymphocytes in arthritic joints were lineage-nega-
tive CD45+ ILCs, whichwere equivalent in ratio betweenRag2/
mice transferred with Csf2/ or WT SKG CD4+ T cells (Figures
4C, 4D, and S2A for gating strategy). We also found a fraction
of synovial-resident ILCs in healthy joints of SKG mice (which
are on the BALB/c background) and othermouse strains (Figures
4E, S3A, and S4). Expansion of these synovial ILCs expressing
Ki-67 was detectable only in inflamed joints, but not in the drain-
ing LNs or bone marrow (BM), suggesting that synovial ILCsunity 48, 1220–1232, June 19, 2018 1223
(legend on next page)
1224 Immunity 48, 1220–1232, June 19, 2018
preferentially expanded in inflamed joints, but might scarcely
migrate to the adjacent lymphoid organs (Figures 4E, 4F,
and S3B).
By flow cytometry, most of the joint-infiltrating ILCs expressed
IL-7Ra, CD25, IL-33Ra, and CD44, while nearly a half of them ex-
pressed c-kit and/or MHC class II, and10%of them expressed
CCR6 (Figure 4G). Further analysis of transcription factors
defining ILC subsets revealed that approximately 60% and 6%
of the ILCs expressed Gata-3 or Rorgt, respectively, indicating
predominant expansion of ILC2s in arthritic joints, as shown in in-
testinal infection (Figures 4H and 4I; Hoyler et al., 2012). Indeed,
GM-CSF-producing ILCs in healthy and inflamed joints ex-
pressed Gata-3 and/or IL-13, which are the signature transcrip-
tion factor and cytokine, respectively, of ILC2s (Figures 4J and
S3A). ILCs with a similar phenotype were also present in normal
joints and expanded in collagen antibody-induced arthritis in
C57/BL6 mice, indicating that the presence and expansion of
GM-CSF-producing synovial ILCs was not dependent on the
mouse genetic background or the mode of arthritis induction
by autoimmune Th17 cells or autoantibody (Figures 4K and
S4). In addition, inflamed joints contained Rorgt-expressing
ILC3s (Figure 4H). As ILC3s were reportedly able to produce
GM-CSF in the intestine to maintain gut homeostasis (Mortha
et al., 2014), we attempted with IL-17-fate reporter SKG mice
to determine whether joint ILC3s, whose signature cytokine is
IL-17, also produced GM-CSF. In correlation with the small per-
centage (6%) of Rorgt-expressing ILC3s shown in Figure 4H,
joint ILCs contained a small fraction (4%) of IL-17-fate re-
porter-positive cells producing GM-CSF, suggesting that a part
of GM-CSF-producing ILCs were derived from ILC3s in this
model (Figure 4L). Synovial ILCs also highly expressed the
transcription factor encoded by Bhlhe40, which reportedly
controlled GM-CSF production by pathogenic Th cells (Fig-
ure 4M; Lin et al., 2014; Martı´nez-Llordella et al., 2013).
To further determine the contribution of these ILCs to arthritis
development, we attempted to selectively deplete ILCs by anti-Figure 4. GM-CSF-Producing ILCs in Inflamed Joints
(A) Flow cytometry analysis of GM-CSF expression by CD4+ T cells and CD4 c
T cells from WT or Csf2/ SKG mice.
(B) Quantitative RT-PCR analysis ofCsf2, Il1b, and Tnf in CD11b+Ly-6G (CD11b+
mannan-treated SKG mice (n = 3). mRNA expression is presented relative to the
(C) Flow cytometry of joint infiltrating cells inRag2/mice transferred with CD4+ T
markers (a cocktail of CD3, CD4, CD8, CD11b, CD11c, CD19, and DX-5).
(D) Proportion of ILCs in Rag2/ mice transferred with CD4+ T cells as shown
the means.
(E) Total cell number of ILCs from healthy or inflamed joints of SKG mice (n = 3).
(F) Flow cytometry of synovial ILCs (CD45.2+ lineage markers-negative Thy1.2+
(G) Flow cytometry of synovial ILCs (CD45.2+ lineage markers-negative Thy1.2+
IL-33Ra, CD44, and MHC2.
(H) Flow cytometry of synovial ILCs (as shown in C) for intranuclear expression o
(I) Proportion of the transcription factor-expressing synovial ILCs (n = 3) as show
(J) Flow cytometry of synovial ILCs (as shown in C) for the expression of GM-CS
(K) Total cell numbers of ILCs from healthy or inflamed joints of C57/BL6 (B6) mice
independent experiments.
(L) Flow cytometry of synovial ILCs for the expression of GM-CSF and FP635 in
(M) Quantitative RT-PCR analysis of Csf2 and Bhlhe40 in splenic naive CD25CD
(N) The effects of ILC depletion on arthritis development. CD4+ T cells (13 106) fr
which were i.v. injected with 500 mg anti-Thy1.2 mAb or control Rat IgG every w
*p < 0.05, **p < 0.01. Data are representative of three independent experiments in
(F), and (N). Vertical bars mean SD in (B), (E), (I), (K), (M), and (N).Thy1.2 mAb in Thy1.2+ Rag2/ mice that had been transferred
with CD4+ T cells from Thy1.1+ congenic SKG mice (Figure 4N).
Multiple injections of 500 mg anti-Thy1.2 mAb every week indeed
reduced the severity of autoimmune arthritis significantly.
Taken together, synovial ILCs selectively expanded in arthritic
joints, secreting GM-CSF and contributing to the development of
autoimmune arthritis.
GM-CSF from Both Radio-Resistant Stromal Cells
Including FLSs and ILCs Is Essential for Autoimmune
Arthritis Development
To assess the contribution of GM-CSF from either stromal
cells or ILCs to autoimmune arthritis, we x-irradiated (6Gy)
Rag2/ or Csf2/Rag2/ mice, reconstituted the mice with
Rag2/ or Csf2/Rag2/ BM cells, transferred to them
Csf2/ SKG CD4+ T cells 6 weeks after BM reconstitution,
and assessed arthritis score 12 weeks after CD4+ T cell transfer
(Figure 5A). Rag2/ BM-transferred x-irradiated Csf2/
Rag2/ mice and Csf2/Rag2/ BM-transferred x-irradiated
Rag2/ mice, in which GM-CSF production was restricted to
ILCs or radio-resistant stromal cells including FLSs, respectively,
developed significantly less severe arthritis than Rag2/ BM-
transferred x-irradiatedRag2/mice, in which both ILCs and ra-
dio-resistant stromal cells produced GM-CSF (Figure 5B).
The percentage of total synovial ILCs expanding in inflamed
joints was comparable between Rag2/ BM transfer and
Csf2/Rag2/ BM transfer, although the total number of syno-
vial ILCs was smaller in the latter chimeras presumably because
of less severe synovial inflammation (Figure 5C, data not shown).
Also, the latter still possessed a small number of recipient-
derived GM-CSF-producing ILCs (Figure 5D), indicating that
reduction, if not complete abrogation, of GM-CSF production
in ILCs was able to attenuate arthritis severity. In addition, by
Csf2/ BM transfer, the proportion of ILCs co-expressing
GM-CSF and IL-13 decreased, with similar proportions of total
IL-13+ ILCs, suggesting that joint inflammation had expandedells among CD45+ joint infiltrating cells in Rag2/ mice transferred with CD4+
), CD11b+Ly-6G+ (Ly-6G+), CD4+ T cells, and ILCs sorted from arthritic joints of
expression of Hprt1.
cells fromWT orCsf2/ SKGmice. Cells were stained for CD45.2 and lineage
in (C). Each symbol represents an individual mouse. Horizontal bars indicate
cells as shown in C) for Ki-67 expression.
cells as shown in C) for cell surface expression of IL-7Ra, CD25, CCR6, c-kit,
f the transcription factor T-bet, Gata-3, Rorgt, and Foxp3.
n in (H).
F, Gata-3, and IL-13.
with collagen antibody-induced arthritis (n = 3). Data are representative of two
arthritic Il17aCre R26RFP635 SKG mice.
44loCD4+ T cells (naive CD4+ T) and synovial ILCs (n = 3) as shown in (C).
om Thy1.1+ SKG mice were adoptively transferred into Thy1.2+ Rag2/mice,
eek (n = 19 each). The severity of arthritis was monitored every week.
(A)–(C), (E)–(J), (L), and (M) and pooled from more than two experiments in (D),
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Figure 5. GM-CSF from ILCs and Radio-Resistant Stromal Cells Is Crucial for Autoimmune Arthritis
(A) Preparation of experimental groups for assessing arthritogenic effects of GM-CSF from ILCs or radio-resistant stromal cells.Rag2/ orCsf2/Rag2/mice
were x-irradiated (X-Rag2/mice) and transferred with BM cells from Csf2/ or WT Rag2/mice. The resulting four groups of BM chimeras were transferred
with CD4+ T cells from Csf2/ SKG mice 6 weeks after BM reconstitution and assessed for arthritis development 12 weeks later.
(B) Arthritis scores of four groups of mice shown in (A).
(C) Proportion of total synovial ILCs from x-irradiated Rag2/ mice reconstituted with Csf2/ or WT Rag2/ BM cells.
(D) Flow cytometry of synovial ILCs for the expression of GM-CSF and IL-13 in arthritic joints of BM chimeras shown in (C).
(E) Proportion of GM-CSF+IL-13, GM-CSF+IL-13+, and GM-CSFIL-13+ synovial ILCs (n = 6 each) as shown in (D).
(legend continued on next page)
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Csf2/ ILCs, which appeared to be hardly pathogenic (Figures
5D and 5E).
To further assess the contribution of ILCs to arthritis develop-
ment, we x-irradiated Thy1.1+ Rag2/mice, reconstituted them
with BM cells from Thy1.1+ Rag2/ mice and Thy1.2+ Csf2/
SKG mice at a 1:1 ratio, and treated the mice 6 weeks later
with a single injection of 20 mg mannan and subsequently with
500 mg anti-Thy1.1 mAb once a week. Anti-Thy-1.1 treatment
selectively depleted synovial Thy1.1+ GM-CSF-producing ILCs,
while control mAb treatment allowed similar expansion of
synovial Thy1.1+ GM-CSF-producing ILCs and Thy1.2+ GM-
CSF-nonproducing ILCs (Figure 5F). This selective depletion of
synovial GM-CSF-producing ILCs significantly reduced the
severity of arthritis (Figure 5G).
These results collectively indicate that GM-CSF from both
ILCs and radio-resistant stromal cells synergistically contributes
to the development of severe autoimmune arthritis in SKG mice.
IL-2, IL-33, and TLR-9 Ligands Control GM-CSF
Production by Synovial ILCs
Given the finding that IL-2, IL-7, and IL-33 control the effector
function of ILC2s in inflamed tissues (Klose and Artis, 2016),
we assessed their contribution to GM-CSF production by
ILCs. Among various tissue homogenates prepared from
normal mice, joint tissues substantially expressed IL-33, which
significantly increased in arthritic joints at both the mRNA and
protein levels compared with unaffected joints (Figures 6A
and 6B). This was consistent with the finding by others that
IL-33 was constitutively expressed in the nucleus of some im-
mune cells and stromal cells in inflamed joints (Fock et al.,
2013; Kaieda et al., 2010). We next sorted synovial ILCs and
treated them in vitro with IL-2, IL-7, or IL-33 alone or in combi-
nation to assess the effects of these cytokines on GM-CSF pro-
duction by ILCs. Intriguingly, IL-2, but not IL-7, in combination
with IL-33 synergistically upregulated GM-CSF production from
synovial ILCs, while the IL-2 and IL-33 combination or the IL-7
and IL-33 combination significantly increased the ILC2 signa-
ture cytokines IL-13 and IL-5 (Figure 6C). We also examined
possible expression of TLRs by synovial ILCs, as reported
with human ILCs in the tonsil and the intestine (Crellin et al.,
2010; Marafini et al., 2015). Quantitative RT-PCR analysis re-
vealed that synovial ILCs highly expressed Tlr2, Tlr3, Tlr4,
and Tlr9 relative to naive Th cells as a negative control (Fig-
ure 6D). Moreover, in vitro stimulation of synovial ILCs with
TLR ligands alone or in combination with IL-33 showed that
stimulation with each TLR ligand alone failed to induce any
GM-CSF production, but CpG DNA, a TLR-9 ligand, in combi-
nation with IL-33 significantly increased GM-CSF production
more than IL-33 alone (Figure 6E). Taken together, IL-33,
IL-2, and TLR-9 ligands, especially their combination, in in-
flamed synovia are able to augment GM-CSF production by sy-
novial ILCs.(F and G) The effects of ILC depletion on arthritis development. Thy1.1+ Rag2/m
Thy1.2+Csf2/ SKGmice. The resulting BM chimeras were i.p. injected with 20 m
or control Rat IgG every week. Flow cytometry of synovial ILCs for GM-CSF and IL
(G). Vertical bars mean SD (n = 8 each).
*p < 0.05, **p < 0.01. Data are representative of three independent experiments in
bars indicate the means in (B), (C), and (E).GM-CSF-Producing ILCs in Synovial Fluid of RA Patients
With the key role of ILC-derived GM-CSF for the development of
arthritis in SKGmice, we next evaluated the proportion and cyto-
kine profile of ILCs in peripheral blood and synovial fluid (SF) ob-
tained from RA or osteoarthritis (OA) patients. All the RA patients
examined fulfilled the RA classification criteria of the American
College of Rheumatology (ACR) and the European League
Against Rheumatism (EULAR) 2010. The patients were 67.9 ±
8.9 (mean ± SD) years old, with disease duration of 25.4 ± 11.8
years. Anti-CCP antibody and rheumatoid factor were positive
in all the patients. Disease activity scores in 28 joints using eryth-
rocyte sedimentation rate (DAS28-ESR) were 3.0 ± 0.5. Among
10 patients, 7 were treated with methotrexate, 6 with biological
or targeted synthetic disease-modifying anti-rheumatic drugs
(tocilizumab; 2, etanercept; 1, golimumab; 1, abatacept; 1, tofa-
citinib; 1), and 9 with glucocorticoids (4.6 ± 2.1 mg/day prednis-
olone). The patients with OA were 77.7 ± 4.5 (mean ± SD) years
old and fulfilled the grade 4 of Kellgren-Lawrence system for
classification of OA. None of the OA patients were treated with
immunosuppressive drugs or glucocorticoids. ILCs comprised
a sizable fraction (3%) of CD45+ hematopoietic cellular ele-
ments in SF from RA patients and were significantly increased
when compared with ILCs in the peripheral blood of RA patients
or those in SF from OA patients (Figures 7A, S2B, and S2C for
gating strategies). Notably, the total numbers of SF ILCs from
RA patients were markedly increased by 100-fold compared
with those from OA patients (Figure 7B). The ratio of ILCs ex-
pressing GM-CSF, IFN-g, or IL-17 significantly increased, in
RA SF compared with RA peripheral blood, with a significant
reduction of the ratio of IL-13-expressing SF ILCs, although the
latter appeared to increase in absolute number in RF SF
compared with OA SF (Figure 7C). The majority of GM-CSF-pro-
ducing cells in SF was CD3+ T cells (80%), followed by CD11b+
myeloid cells (15%) and ILCs (5%) (Figures 7D and 7E). Thus,
GM-CSF-producing synovial ILCs greatly expanded in inflamed
joints of RA patients and shared a similar inflammatory signature
between mice and humans. The difference in the cytokine
expression profile, especially in IFN-g and IL-13 expression,
and in the cellular frequencies between human andmouse syno-
vial ILCs could be attributed, at least in part, to the methods of
sample collections (synovial tissues in mice versus SF in hu-
mans) as well as medications in the patients, different disease
courses and stages, variable treatment periods, heterogeneity
of disease types, and heterogenous genetic backgrounds of
humans.
DISCUSSION
The main finding in this report is that arthritogenic Th17 cells
are able to stimulate via IL-17 radio-resistant stromal cells
including FLSs to secrete GM-CSF, and also synovial-resident
ILCs to expand and produce GM-CSF in inflamed joints.ice were x-irradiated and transferred with BM cells from Thy1.1+ Rag2/ and
gmannan 6 weeks later, followed by i.v. injection with 500 mg anti-Thy1.1 mAb
-13 expression (F). Arthritis scores in each group of micemonitored every week
(D) and (F), and pooled from three experiments in (B), (C), (E), and (G). Horizontal
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Figure 6. Control of GM-CSF Production in Synovial ILCs by IL-2, IL-33, and TLR-9 Ligands
(A) Quantity of the active form IL-33 assessed by ELISA (Biolegend, Mouse IL-33 ELISA kit) in indicated tissue homogenates.
(B) Quantitative RT-PCR for Il33 expression and ELISA for IL-33 protein in arthritic or control joints. Symbols represent individual mice.
(C) Production of cytokines by synovial ILCs. Synovial ILCs (5 3 103) from arthritic joints were purified and cultured for 24 hr with rhIL-2 (20 U/mL), rmIL-7
(20 ng/mL), and rmIL-33 (20 ng/mL) alone or in combination. The concentration of IL-5, IL-13, and GM-CSF in the supernatant was measured (n = 3).
(legend continued on next page)
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Figure 7. GM-CSF-Producing ILCs in Syno-
vial Fluid of RA Patients
(A) The presence of ILCs (defined as CD45+
CD3CD4CD8CD11bCD11cCD19CD56)
from peripheral blood (PB) or synovial fluid (SF) of
a patient with RA or OA (left). The percentages of
ILCs in PB and SF from individual RA (n = 13) or OA
(n = 6) patients. The lines indicate the sample pairs
of the same patients (right).
(B) Total numbers of ILCs in 1 mL of SF from OA
and RA patients (n = 6). Vertical bars indicate SD.
(C) Flow cytometry analysis of IFN-g, IL-13, IL-17,
and GM-CSF expression by ILCs (gated as in A) in
PB or SF of a RA patient (top). The percentages of
cytokine-producing ILCs from individual RA pa-
tients (n = 11) (bottom).
(D) Gating strategies for GM-CSF+CD45+ lineage
markers-negative (ILCs), GM-CSF+CD45+CD3
CD11b+ (myeloid cells), and GM-CSF+CD45+
CD11bCD3+ cells (T cells).
(E) Proportion of GM-CSF-producing cells (n = 3).
Vertical bars indicate SD. Symbols represent in-
dividual samples. Horizontal bars indicate the
means.
*p < 0.05, **p < 0.01.Abrogation of GM-CSF production by either the stromal cells or
ILCs is able to prevent Th17 cell-mediated arthritis, while GM-
CSF from arthritogenic Th cells is contributory to but not
mandatory for arthritis development, at variance with a crucial
role of Th17 cell-derived GM-CSF in mouse EAE (Codarri
et al., 2011; El-Behi et al., 2011). The present results do not
exclude possible contribution of GM-CSF-producing radio-(D) Quantitative RT-PCR analysis of the expression of indicated TLR genes in naive CD4+ T cells and synov
(E) GM-CSF production by synovial ILCs. Synovial ILCs (53 103) were cultured for 24 hr with poly(I:C) (1 mg/m
combination with rmIL-33 (20 ng/mL). The concentration of GM-CSF in the supernatant was measured (n =
**p < 0.01. Data are representative of at least two independent experiments. Horizontal bars indicate the mea
Immresistant lymphocytes and non-lymphoid
stromal cells other than ILCs and FLSs,
inside or outside the joint, to disease
manifestation in SKG mice and BM
chimeras. Nevertheless, these results
strongly support the notion that GM-
CSF-producing radio-resistant stromal
cells and synovial ILCs are critical com-
ponents of a key inflammatory cellular
cascade for the development of autoim-
mune arthritis.
It has been well substantiated in RA
that FLSs in the synovial intimal lining
are key effector cells producing large
amounts of inflammatory mediators and
proteolytic enzymes, such as matrix met-
alloproteinases (MMPs) and cathepsins,
which degrade cartilage and bone (Bar-
tok and Firestein, 2010). IL-1 and TNF-a
synergistically induce GM-CSF in FLSs
(Alvaro-Gracia et al., 1991). Stimulation
with IL-17 in combination with IL-1 andTNF-a enhances the production of IL-6 andMMPsby FLSs (Cha-
baud et al., 2001). Here, we have shown that in vitro stimulation
of SKG FLSs with IL-17 increases FLS-derived production of
neutrophil-recruiting chemokines and GM-CSF, as previously
reported with RA synoviocytes (Fossiez et al., 1996; Varas
et al., 2015) and that loss of GM-CSF production by radio-resis-
tant stromal cells including FLSs prevents arthritis development.ial ILCs as shown in Figure 4M (n = 3).
L), LPS (1 mg/mL), and CpG DNA (1 mM) alone or in
3).
ns in (A) and (B). Vertical bars indicate SD in (C)–(E).
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Since the induction of arthritis is dependent on IL-17 from auto-
immune Th cells in our model (Hirota et al., 2007a), it is likely that
Th17 cells stimulated the stromal cells via IL-17 to produce
GM-CSF. This can be a key early event to initiate micro-inflam-
mation, which in turn mediates a downstream inflammatory
cascade, leading to overt joint inflammation accompanying the
infiltration and expansion of Th17 cells, ILCs, neutrophils, and
inflammatory monocytes.
GM-CSF-producing synovial-resident ILCs expand in in-
flamed joints and augment autoimmune arthritis. Among group
1, 2, and 3 ILCs, which are classified by their expression of
signature cytokines and master transcription factors (Buono-
core et al., 2010; Eberl et al., 2015; Spits et al., 2013), ILC2s
mediate type 2 immunity including allergic reactions and host
defense against parasite infections (Moro et al., 2010; Neill
et al., 2010; Saenz et al., 2010; Wilhelm et al., 2011). We
have shown here that CD25+IL-33Ra+GATA-3+ ILC2s actively
secreting GM-CSF are a major ILC subset expanding in in-
flamed joints and that depletion of total ILCs by anti-Thy1 anti-
body or loss of GM-CSF production in ILCs, without affecting
the expansion of GM-CSF-nonproducing synovial ILCs, is
able to effectively prevent autoimmune arthritis. Notably, these
GM-CSF-producing synovial ILCs are physiologically present in
healthy joints of any mouse strain. In addition, the presence of
synovial ILCs in healthy joints and the paucity of ILCs in
lymphoid organs or blood (Bando et al., 2015; Huang et al.,
2015) indicate that ILC’s precursors with the capacity to give
rise to ILC1s, ILC2s, and ILC3s preferentially migrate from the
BM, their primary site of generation, and differentiate into
GM-CSF-producing ILCs in the synovia. While bidirectional
plasticity between ILC1s and ILC3s was recently observed in
the intestinal lamina propria (Bernink et al., 2015), synovial
ILC2s did not appear to originate from ILC3s, which is the ma-
jor GM-CSF producer in the intestine of mice and humans
(Glatzer et al., 2013; Mortha et al., 2014). These results collec-
tively suggest that GM-CSF may not be an ILC subset-specific
cytokine but can be produced by ILC1s, ILC2s, and ILC3s in an
environment-dependent manner, as a recent comprehensive
transcriptome analysis of ILC subsets showed Csf2 as one of
shared transcriptional signatures (Robinette et al., 2015). In
addition, Bhlhe40, which transcriptionally increases the expres-
sion of proinflammatory cytokines including GM-CSF in Th1
and Th17 cells (Lin et al., 2014; Martı´nez-Llordella et al.,
2013), may be another shared molecule driving Csf2 among
ILC subsets and may also induce the pathogenicity of GM-
CSF-producing synovial ILCs in autoimmune arthritis. It re-
mains to be determined how such synovial ILCs are maintained
as a cellular constituent of the normal joint and what physiolog-
ical roles GM-CSF-producing synovial ILCs play in healthy
joints.
GM-CSF production by ILCs is stimulated by the alarmin
IL-33 and further enhanced by IL-2 and TLR-9 ligands. Syno-
vial ILCs highly expressed CD25 and IL-33Ra, enabling their
ligands IL-2 and IL-33, which are abundantly present in in-
flamed joints, to control GM-CSF production. In addition to
well-characterized IL-2- and IL-33-dependent ILC2 control,
we have shown in the current study that synovial ILCs ex-
pressed functional cytoplasmic TLR9, which may sense
mitochondrial DNA (containing unmethylated CpG repeats, a1230 Immunity 48, 1220–1232, June 19, 2018bacterial molecular motif) possibly released as an endogenous
damage-associated molecular pattern (DAMPs) (Zhang et al.,
2010). In addition, extracellular mitochondrial DNA, which
could experimentally induce arthritis in animals, was reported
to be detectable in synovial fluid of RA patients (Collins
et al., 2004). Taken together, synovial ILCs expressing CD25,
IL-33Ra, and cytoplasmic TLR9 may sense IL-2, IL-33, and
self DNA, which are produced by pathogenic Th cells or
released from necrotic joint inflammatory cells, leading to their
production of GM-CSF (Xu et al., 2008).
GM-CSF is abundant in RA synovium and upregulated by IL-1
and TNF-a and by IL-17 (Alvaro-Gracia et al., 1991; Varas et al.,
2015). Anti-GM-CSFRa or anti-GM-CSF showed significant clin-
ical efficacy in RA patients without major adverse effects such as
pulmonary alveolar proteinosis, which is caused by autoanti-
bodies against GM-CSF (Behrens et al., 2015; Burmester et al.,
2013). As GM-CSF-producing ILCs, stromal cells, and T cells
sense different inflammatory cues such as DAMPs, inflammatory
cytokines, and recognition of self-antigens, respectively, in joint
inflammation, the importance of each source of GM-CSF may
depend on the phase of joint inflammation. For example, GM-
CSF from ILCs appears to play a key role in the initiation of auto-
immune arthritis, while T cell-derived GM-CSFmay contribute to
chronic progression of the disease. For better control of local
tissue inflammation in RA and other immunological diseases, it
is required to further elucidate how GM-CSF production is
controlled in T cells, FLSs, and ILCs at various inflammation
stages, and how these cell populations interact spatio-tempo-
rarily via GM-CSF.
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Software and Algorithms
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Other
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
SKG (Sakaguchi et al., 2003), Il17a/ SKG (Hirota et al., 2007a), Rag2/ (Setoguchi et al., 2005),Csf2/ (Sonderegger et al., 2008),
Thy1.1 congenic (Setoguchi et al., 2005) mice were used. C57/BL6J mice were purchased from CLEA Japan. Il17aCre, R26RFP635,
and R26ReYFP mice were backcrossed to SKG for more than eight generations (Hirota et al., 2011). Csf2/ SKG, Csf2/ Rag2/,
Il17aCre R26RFP635, Il17aCre R26ReYFP, Thy1.1 congenic SKG or Rag2/ mice were generated by crossing the strains described
above. All the genetically modified mouse strains used in this study were on the BALB/c background and kept under specific path-
ogen-free conditions. Bothmale and femalemice at 8-12weeks of agewere used for all the experiments. All animal experiments were
approved by the Animal Ethical Committee of Immunology Frontier Research Center, Osaka University and Institute for Frontier Life
and Medical Sciences, Kyoto University, and performed in accordance with institutional guidelines.
Induction of autoimmune arthritis
Arthritis was induced by either a single injection of 20 mgmannan (Sigma-Aldrich) intraperitoneally (Hashimoto et al., 2010), or adop-
tive transfer of CD4+ T cells intravenously (i.v.) (Hirota et al., 2007a). CD4+ T cells were sorted from the spleen and peripheral LNs of
SKG mice using MACS CD4 microbeads and LS column (Miltenyi Biotec) according to the manufacturer’s instruction. For depletion
of ILCs, purified anti-Thy1.1 (19E12; Bio X cell), anti-Thy1.2 (30H12; Bio X Cell) or isotype control Rat IgG2b (LTF-2; Bio X Cell)Immunity 48, 1220–1232.e1–e5, June 19, 2018 e3
antibody was i.v. injected. Joint swelling was scored as follows: 0, no joint swelling; 0.1, swelling of one finger joint; 0.5, mild swelling
of wrist or ankle; 1.0, severe swelling of wrist or ankle. Scores for all fingers of forepaws and hindpaws, wrists and ankles were totaled
for each mouse.
Patient information
Detailed information about RA or OA patients is described in the section of Results. Synovial fluid samples from RA or OA patients
were obtained at the time of arthrocentesis or surgical operation and cellular fractions were analyzed by flow cytometry. Samples
from peripheral blood were taken from the same patients at different time points. Peripheral bloodmononuclear cells were separated
using Ficoll-Paque PLUS (GE Healthcare). This study has been approved by the Ethical Committee of Kyoto University. Written
informed consent was obtained from all the participants.
METHOD DETAILS
Flow cytometry
The following monoclonal antibodies were used for flow cytometry analysis (BD FACSCantoII) and cell sorting (BD FACSAria SORP):
anti-mouse CCR6 (29-2L17, Biolegend), CD3e (145-2C11, BD Biosciences), CD4 (RM4-4, Biolegend), CD8 (53-6.7, Biolegend),
CD11b (M1/70, Biolegend), CD11c (HL3, BD Biosciences), CD16/32 (2.4G2, BD Biosciences), CD19 (1D3, BD Biosciences),
CD25 (PC61, BD Biosciences), CD44 (IM7, BD Biosciences), CD45.2 (104, Biolegend), c-Kit (2B8, Biolegend), Foxp3 (FJK-16S,
eBioscience), Gata-3 (TWAI, eBioscience), GM-CSF (MP1-22E9, BD Biosciences), GM-CSFRa (698423, R&D systems), IFN-g
(XMG1.2, eBioscience), IL-13 (eBio13A, eBioscience), IL-17 (TC11-18H10.1, Biolegend), IL-7Ra (SB/199, BD Biosciences), Ki-67
(MKI67, BD Biosciences), IL-33Ra (D1H9, Biolegend), Ly-6C (AL-21, BD Biosciences), Ly-6G (1A8, Biologend), MHC2
(M5/114.15.2, Biolegend), Pan-NK (DX-5, eBioscience), Podoplanin (8.1.1, Biolegend), Rorgt (AFKJS-9, eBioscience), TCR-b
(H57-597, Biolegend), T-bet (4B10, Biolegend), Thy1.1 (OX-7, BD Biosciences), Thy1.2 (53-2.1, Biolegend), anti-human CD3
(UCHT1, Biolegend), CD4 (OKT4, Biolegend), CD8 (SK1, Biolegend), CD11b (M1/70, eBioscience), CD11c (3.9, Biolegend), CD19
(HIB19, Biolegend), CD45 (HI30, Biolegend), CD56 (HCD56, Biolegend), GM-CSF (BVD2-21C11, Biolegend), IFN-g (4S.B3, Bio-
legend), IL-13 (JES10-5A2, Biolegend), IL-17 (BL168, Biolegend), PECy7-Streptavidin (BD Biosciences). For intracellular staining
for transcription factors, cells were stained using Foxp3 staining buffer set (eBioscience) according to themanufacturer’s instruction.
For intracellular staining for cytokines, cells were restimulated in IMDM buffer (Sigma-Aldrich) supplemented with 5% FBS (GIBCO),
penicillin-streptomycin (Nacalai Tesque), 2-Mercaptoethanol (GIBCO), GlutaMAX (GIBCO), sodium pyruvate (GIBCO), and MEM
NEAA (GIBCO) for 4 h with phorbol 12-myristate 13-acetate (50 ng/ml; Sigma-Aldrich) and ionomycin (500 ng/ml; Sigma-Aldrich)
in the presence of brefeldin A (1 mg/ml; Merck), fixed with 3.7% formaldehyde (Sigma-Aldrich), permeabilized with 0.1% NP-40
(Nacalai Tesque), and stained with FACS buffer consisting of HBSS (Nacalai Tesque) supplemented with 2% FBS (GIBCO) and
0.1% sodium azide (Nacalai Tesque). All the FACS data were analyzed on FlowJo software.
Preparation of FLS from inflamed joints
Inflammatory synovial cells were prepared by cutting the synovial tissues from arthritic joints into small pieces, followed by enzymatic
digestion for 30 min at 37C in plain IMDM buffer (Sigma-Aldrich) with Liberase TM (0.25 mg/ml; Roche), and then by mashing the
digested tissues through 70-mm mesh filter (BD Biosciences). The resultant single cell suspension of synovial tissues was used
for flow cytometry or cell sorting experiments. Non-hematopoietic synovial cells adherent to culture dishes were passaged several
times without any stimulation in DMEMmedium (Nacalai Tesque) supplemented with 20% FBS (GIBCO) and penicillin-streptomycin
(Nacalai Tesque) in order to remove synovial immune cells and used as FLS.
Quantitative RT-PCR
Total RNA from FLS or inflammatory immune cells isolated from arthritic joints was extracted with TRIzol (Invitrogen) and reverse
transcribed with SuperScript VILO (Invitrogen) in accordance with the manufacturer’s instructions. The resultant cDNAs served as
templates for the amplification of genes of interest and a housekeeping gene by LightCycler 480 (Roche) with qPCR Master
Mix (TOYOBO) and ABI TaqMan Gene Expression assays (Bhlhe40; Mm00478593_m1, Ccl20; Mm01268754_m1,
Csf2; Mm00438328_m1, Cxcl1; Mm04207460_m1, Cxcl5; Mm00436451_g1, Hprt; Mm01545399_m1, Il1b; Mm00434228_m1,
Il6; Mm00446190_m1, Il33; Mm00505403_m1, Lif; Mm00434762_g1, Nfkbiz; Mm00600522_m1, Tlr1; Mm00446095_m1, Tlr2;
Mm00442346_m1, Tlr3; Mm01207404_m1, Tlr4; Mm00445273_m1, Tlr5; Mm00546288_s1, Tlr6; Mm02529782_s1, Tlr7;
Mm00446590_m1, Tlr9; Mm00446193_m1, Tnf; Mm00443260_g1, Zc3h12a; Mm00462533_m1). The level of target gene expression
was quantified after normalization to Hprt expression.
Culture and cytokine measurement of synovial ILCs
Synovial ILCs (CD3-, CD4-, CD8-, CD11b-, CD11c-, CD19-, Pan-NK-, CD45.2+, and Thy1.2+) from inflamed joints were purified by flow
cytometry and cultured overnight in the presence of rhIL-2 (20 U/ml, Shionogi Co.), rmIL-7 (20 ng/ml, R&D systems), rmIL-33
(20 ng/ml, R&D systems), Poly(I:C) (1 mg/ml, InvivoGen), LPS (1 mg/ml, InvivoGen), and CpG DNA (1 mM, InvivoGen). The concentra-
tion of IL-5, IL-13, and GM-CSF in the culture supernatant was measured using BD Cytometric Bead Array (BD Biosciences).e4 Immunity 48, 1220–1232.e1–e5, June 19, 2018
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are shown as mean ± standard error of mean (SEM) or mean ± standard deviation (SD). Statistical analysis was done with
GraphPad PRISM. A two-tailed t test was used for statistical analysis. ANOVA and Bonferroni post-test were used for grouped
data analysis. P value of < 0.05 was considered statistically significant. Sample sizes for all shown data can be found in the figure
legends.Immunity 48, 1220–1232.e1–e5, June 19, 2018 e5
